Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven relapsed or refractory progressive solid
tumor that is not amenable to treatment with standard therapies No brain involvement or
leptomeningeal disease

PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Postmenopausal Performance
status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil
count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL
No bleeding or clotting abnormalities Hepatic: Bilirubin no greater than 1.5 times upper
limit of normal (ULN) AST or ALT no greater than 2.5 times ULN Alkaline phosphatase no
greater than 2.5 times ULN Renal: Creatinine no greater than 1.4 mg/dL Cardiovascular:
Normal cardiac function by 12 lead ECG Other: No unstable systemic disease or uncontrolled
infection that would preclude study participation No concurrent infection requiring
antibiotics Not pregnant or nursing Negative pregnancy test Fertile patients must use
effective contraception during and for 70 days after study No psychologic, familial,
sociologic, or geographic condition that could preclude compliance HIV negative HTLV-1
negative Hepatitis B surface antigen negative No other prior or concurrent malignancy
except basal cell skin cancer or carcinoma in situ of the cervix No allergy to protein
therapeutics

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and
recovered Chemotherapy: At least 4 weeks since prior chemotherapy and recovered Endocrine
therapy: At least 4 weeks since prior hormonal antitumor therapy No concurrent steroids or
hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy and recovered
Concurrent radiotherapy allowed Surgery: Greater than 4 weeks since prior surgery except
biopsy or fine needle aspiration of tumor masses Other: At least 4 weeks since other prior
investigational drugs or therapies No other concurrent anticancer treatments No other
concurrent investigational therapy